| NCT03206047 ↗Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Phase 1, Phase 2 | 조기 종료 | 중재 4개 · 상세 참조Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma | 등록 9명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- Atezolizumab · DEC-205/NY-ESO-1 Fusion Protein CDX-1401 · Guadecitabine · Poly ICLC
- 등록 질환
- Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
- 등록 1차 평가변수
- Incidence of Adverse Events (AE) (Phase I); Progression Free Survival (PFS) (Phase IIb)
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 9
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT06890338 ↗A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | 모집 중 | 중재 3개 · 상세 참조Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · Neoadjuvant | 등록 140명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- Carboplatin · Mirvetuximab Soravtansine · Bevacizumab
- 등록 질환
- Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · Neoadjuvant
- 등록 1차 평가변수
- Objective Response (OR) by Independent Central Review (ICR)
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 140
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT04561362 ↗Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Phase 1, Phase 2 | 진행 중 · 모집 종료 | 중재 2개 · 상세 참조Urinary Bladder Neoplasm · Triple Negative Breast Neoplasms · Hormone Receptor Positive, HER2-negative Neoplasms · Hormone Receptor Positive, HER2-low Neoplasms · Breast Neoplasms · Non-Small-Cell Lung Neoplasms · Ovarian Neoplasm · Advanced Solid Tumor | 등록 329명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- BT8009 · Pembrolizumab
- 등록 질환
- Urinary Bladder Neoplasm · Triple Negative Breast Neoplasms · Hormone Receptor Positive, HER2-negative Neoplasms · Hormone Receptor Positive, HER2-low Neoplasms · Breast Neoplasms · Non-Small-Cell Lung Neoplasms · Ovarian Neoplasm · Advanced Solid Tumor
- 등록 1차 평가변수
- Parts A-1, A-2 and C: Number of participants with treatment emergent adverse events, receiving BT8009 as a monotherapy or in combination with pembrolizumab to assess safety and tolerability.; Parts A-1 and A-2 (escalations): Number of participants with dose limiting toxicities on BT8009 as a monotherapy or in combination with pembrolizumab; Part B1-B7: Objective response rate (ORR) to assess the clinical activity of BT8009 as a monotherapy or in combination with pembrolizumab using RECIST 1.1.;
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 329
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT05544929 ↗A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Phase 1 | 진행 중 · 모집 종료 | 중재 2개 · 상세 참조Carcinoma, Non-Small-Cell Lung · Cutaneous Melanoma · Carcinoma, Renal Cell · Carcinoma, Ovarian Epithelial · Nasopharyngeal Carcinoma · Carcinoma, Thymic · Anal Cancer · Mesothelioma · Esophagogastric Cancer · High Microsatellite Instability Colorectal Carcinoma · Squamous Cell Carcinoma of Head and Neck · Triple Negative Breast Neoplasms | 등록 126명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- KFA115 · pembrolizumab
- 등록 질환
- Carcinoma, Non-Small-Cell Lung · Cutaneous Melanoma · Carcinoma, Renal Cell · Carcinoma, Ovarian Epithelial · Nasopharyngeal Carcinoma · Carcinoma, Thymic · Anal Cancer · Mesothelioma · Esophagogastric Cancer · High Microsatellite Instability Colorectal Carcinoma · Squamous Cell Carcinoma of Head and Neck · Triple Negative Breast Neoplasms
- 등록 1차 평가변수
- Incidence and severity of dose limiting toxicities (DLTs) during the DLT evaluation period of single-agent KFA115 (dose escalation only); Incidence and severity of dose limiting toxicities (DLTs) during the DLT evaluation period of KFA115 in combination with pembrolizumab (dose escalation only); Incidence and severity of adverse events (AEs) and serious adverse events (SAEs); Frequency of dose interruptions, reductions; Dose intensity
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 126
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT07360314 ↗Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | Phase 1 | 모집 중 | 중재 2개 · 상세 참조Advanced Solid Tumors | 등록 138명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- M7437 · M7437
- 등록 질환
- Advanced Solid Tumors
- 등록 1차 평가변수
- Dose-escalation Cohort: Occurences of Dose Limiting Toxicities (DLTs); Dose-escalation Cohort: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) and Adverse Event (AEs)
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 138
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT06257264 ↗A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Phase 1 | 진행 중 · 모집 종료 | 중재 3개 · 상세 참조Breast Cancer · Small Cell Lung Cancer · Ovarian Cancer · Gastric Cancer · Hormone-receptor-positive Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Advanced Solid Tumor · Endometrial Cancer · Prostate Cancer · TNBC - Triple-Negative Breast Cancer · GastroEsophageal Cancer · Bladder Cancer | 등록 103명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- BG-68501 · Fulvestrant · BGB-43395
- 등록 질환
- Breast Cancer · Small Cell Lung Cancer · Ovarian Cancer · Gastric Cancer · Hormone-receptor-positive Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Advanced Solid Tumor · Endometrial Cancer · Prostate Cancer · TNBC - Triple-Negative Breast Cancer · GastroEsophageal Cancer · Bladder Cancer
- 등록 1차 평가변수
- Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs); Part 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-68501; Part 1: Recommended dose(s) for Expansion (RDFE) of BG-68501 monotherapy in participants with solid tumors; Part 1: RDFE of BG-68501 in combination with fulvestrant and BGB-43395 in participants with HR+/HER2- BC; Part 2: Objective Response Rate (ORR)
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 103
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT05227326 ↗AOH1996 for the Treatment of Refractory Solid Tumors | Phase 1 | 모집 중 | 중재 1개 · 상세 참조Refractory Malignant Solid Neoplasm · Osteosarcoma · Leiomyosarcomas · Synovial Sarcomas · Ovarian Cancer · Non-Small Cell Lung Cancer · Pancreatic Cancer | 등록 92명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- PCNA Inhibitor AOH1996
- 등록 질환
- Refractory Malignant Solid Neoplasm · Osteosarcoma · Leiomyosarcomas · Synovial Sarcomas · Ovarian Cancer · Non-Small Cell Lung Cancer · Pancreatic Cancer
- 등록 1차 평가변수
- Incidence of adverse events (AEs); Dose limiting toxicities
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 92
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT07504588 ↗Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy | Phase 2 | 모집 중 | 중재 6개 · 상세 참조Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma · Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma · Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma · Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma · Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma · Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma | 등록 87명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- Anti-VEGF Monoclonal Antibody · Bevacizumab · Carboplatin · Gemcitabine · Pegylated Liposomal Doxorubicin Hydrochloride · Sacituzumab Govitecan
- 등록 질환
- Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma · Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma · Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma · Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma · Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma · Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
- 등록 1차 평가변수
- Progression-free survival
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 87
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT05059522 ↗Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | Phase 3 | 진행 중 · 모집 종료 | 중재 8개 · 상세 참조Advanced Malignancies · NSCLC · Ovarian Cancer · Urothelial Cancer · Solid Tumors | 등록 77명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- Avelumab · Lorlatanib · Talazoparib · Pemetrexed · Axitinib · CMP 001 · Utomilumab · PF04518600
- 등록 질환
- Advanced Malignancies · NSCLC · Ovarian Cancer · Urothelial Cancer · Solid Tumors
- 등록 1차 평가변수
- Number of participants with adverse events leading to permanent discontinuation of study intervention; Number serious adverse events reported for all participants
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 77
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT06582017 ↗Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Phase 1 | 모집 중 | 중재 1개 · 상세 참조Ovarian Cancer · Pancreas Cancer · Urothelial Carcinoma · Renal Cell Carcinoma · Hepatocellular Carcinoma · Gastrointestinal Cancer · Lung Cancer · Prostate Cancer · Breast Cancer | 등록 100명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- QXL138AM Injection every 2 weeks by IV Infusion
- 등록 질환
- Ovarian Cancer · Pancreas Cancer · Urothelial Carcinoma · Renal Cell Carcinoma · Hepatocellular Carcinoma · Gastrointestinal Cancer · Lung Cancer · Prostate Cancer · Breast Cancer
- 등록 1차 평가변수
- Incidence of Adverse Events
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 100
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT06143527 ↗Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for PCOS | Phase 1 | 모집 중 | 중재 1개 · 상세 참조Polycystic Ovary Syndrome (PCOS) · Polycystic Ovary Syndrome · PCOS | 등록 20명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
- 등록 질환
- Polycystic Ovary Syndrome (PCOS) · Polycystic Ovary Syndrome · PCOS
- 등록 1차 평가변수
- Safety: Adverse Events
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 20
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT07715747 ↗A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | Phase 1 | 모집 중 | 중재 1개 · 상세 참조Solid Tumor · Metastatic Ovary Cancer · Metastatic Gastric Cancer · Metastatic Endometrial Carcinoma | 등록 128명2026-10-19중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- TJ037130
- 등록 질환
- Solid Tumor · Metastatic Ovary Cancer · Metastatic Gastric Cancer · Metastatic Endometrial Carcinoma
- 등록 1차 평가변수
- Incidence,type,severity and correlation with study treament of AEs
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 128
- 등록자료 최종 게시 갱신
- 2026-10-19
|
|---|